Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	42.07	36.53	24.86	37.04	7.66
Revenue Growth (YoY)	15.17%	46.93%	-32.89%	383.83%	-68.94%
Cost of Revenue	143.92	115.2	105.91	77.64	49.99
Gross Profit	-101.85	-78.67	-81.05	-40.59	-42.34
Selling, General & Admin	43.75	35.5	30.03	17.6	9.87
Operating Expenses	43.75	35.5	30.03	17.6	9.87
Operating Income	-145.6	-114.17	-111.07	-58.19	-52.2
Interest & Investment Income	7.89	6.62	1.46	0.5	0.11
Other Non Operating Income (Expenses)	7.61	5.94	1.49	-0.25	0.12
Pretax Income	-130.09	-101.61	-108.12	-57.94	-51.97
Income Tax Expense	0.21	0.13	0.05	0.29	-
Net Income	-130.3	-101.74	-108.18	-58.24	-51.97
Net Income to Common	-130.3	-101.74	-108.18	-58.24	-51.97
Shares Outstanding (Basic)	109	95	88	62	32
Shares Outstanding (Diluted)	109	95	88	62	32
Shares Change (YoY)	15.50%	7.69%	41.40%	94.50%	255.37%
EPS (Basic)	-1.19	-1.08	-1.23	-0.94	-1.63
EPS (Diluted)	-1.19	-1.08	-1.23	-0.94	-1.63
Free Cash Flow	-132.26	-119.51	-116.77	-61.36	68.97
Free Cash Flow Per Share	-1.21	-1.26	-1.33	-0.99	2.16
Gross Margin	-242.10%	-215.38%	-	-109.59%	-
Operating Margin	-346.09%	-312.57%	-446.79%	-157.09%	-681.82%
Profit Margin	-309.73%	-278.55%	-435.14%	-157.21%	-678.84%
Free Cash Flow Margin	-314.38%	-327.18%	-469.72%	-165.66%	900.84%
EBITDA	-143.1	-111.76	-109.46	-57.29	-51.48
EBITDA Margin	-	-	-	-154.67%	-
D&A For EBITDA	2.5	2.42	1.61	0.9	0.72
EBIT	-145.6	-114.17	-111.07	-58.19	-52.2
EBIT Margin	-	-	-	-157.09%	-
Revenue as Reported	42.07	36.53	24.86	37.04	7.66

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q